Echo Therapeutics Announces Positive Results of a Clinical Study of its Transdermal Continuous Glucose Monitoring System
Advertisement
Echo Therapeutics announced positive results of a clinical study of its Symphony(TM) Transdermal Continuous glucose Monitoring (tCGM) System in patients with Type 1 and Type 2 diabetes. Echo's non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and the Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin permeation control. Echo's Symphony tCGM System is designed to provide both diabetics and hospital patients with a reliable, affordable, comfortable-to-wear, and easy-to-use, needle-free continuous glucose monitoring device.
"This study represents another major advancement in our Prelude and Symphony development programs," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We have now successfully used Prelude, our new needle-free skin preparation system, in combination with our non-invasive Symphony tCGM technology. Data from this study demonstrate that Symphony, using Prelude, is safe, accurate and reliable at monitoring glucose levels. We look forward to continuing progress with our Symphony development program throughout the year."
After Prelude skin permeation, Symphony tCGM biosensors were applied to ten subjects with Type 1 or Type 2 diabetes. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300STAT PLUS laboratory analyzer. At the conclusion of the 24-hour observation period, the test skin sites were inspected for redness or any other undesirable effects.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Pierre Fabre Pharmaceuticals Announce Initiation of Phase IIa Clinical Trial Program for F17464 in Schizophrenia
Genzyme: Myozyme Receives Positive Opinion from European Regulatory Committee - Proposed Indication Includes All Patients with Pompe Disease
Liquid salts deliver drugs through the skin with enhanced efficacy and reduced toxicity
New Phase II Data on Millennium's Proteasome Inhibitor Holds Promise for Patients with Refractory Multiple Myeloma
BTG: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
SEQUENOM and National Institutes of Health Expand Relationship for Gene Expression - Agreement Builds on Success of Previous SNP Genotyping Research
Muscle-Targeted Gene Therapy Reverses Rare Muscular Dystrophy in Mice
Study finds 'mad cow disease' in cattle can spread widely in ANS before detectable in CNS
Simple and Fast Method for Radiolabelling Antibodies against Breast Cancer - Using UV light, radiolabelled antibodies can be produced in just 15 minutes
